skip to main content

DOAC renal monitoring — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRenal and Hepatic ImpairmentDOAC renal monitoringGPhC CRA

A patient with cirrhosis, coagulopathy and clinically significant hepatic disease is discharged on edoxaban for atrial fibrillation. What should the pharmacist do?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Query edoxaban in clinically significant hepatic disease

Edoxaban is contraindicated or not recommended in hepatic disease associated with coagulopathy and clinically relevant bleeding risk. The anticoagulant strategy needs prescriber review based on liver severity, bleeding and stroke risk rather than INR titration of a DOAC.

Reference: BNF: edoxaban: https://bnf.nice.org.uk/drugs/edoxaban/